Cargando…

Infusion Therapies in the Treatment of Parkinson’s Disease

Oral levodopa is the gold-standard therapy for treating Parkinson’s disease (PD) but after a few years of treatment the therapeutic window narrows, and patients often experience various treatment-related complications. Patients in this advanced PD stage may benefit from alternative therapy, such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Laar, Teus, Chaudhuri, K. Ray, Antonini, Angelo, Henriksen, Tove, Trošt, Maja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473148/ https://www.ncbi.nlm.nih.gov/pubmed/37334617 http://dx.doi.org/10.3233/JPD-225112

Ejemplares similares

Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review
por: Moes, Harmen R., et al.
Publicado: (2023)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

Introduction: The Gut-Brain Axis in Parkinson’s Disease
por: van Laar, Teus
Publicado: (2019)

Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review
por: Volkmann, Jens, et al.
Publicado: (2013)

Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
por: Henriksen, Tove, et al.
Publicado: (2021)

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
por: Leta, Valentina, et al.
Publicado: (2022)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

Impact of Infusion Therapies on Quality of Life in Advanced Parkinson’s Disease
por: Constantin, Viorelia A, et al.
Publicado: (2023)

Close relationships in Parkinson´s disease patients with device‐aided therapy
por: Scharfenort, Monica, et al.
Publicado: (2021)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
por: Leta, Valentina, et al.
Publicado: (2021)

Impact of advanced Parkinson’s disease on caregivers: an international real-world study
por: Martinez-Martin, Pablo, et al.
Publicado: (2023)

An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function
por: Van Laar, Amber D., et al.
Publicado: (2021)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Self-Reported Visual Complaints in People with Parkinson’s Disease: A Systematic Review
por: van der Lijn, Iris, et al.
Publicado: (2022)

Cognitive decline in Parkinson’s disease: the complex picture
por: Biundo, Roberta, et al.
Publicado: (2016)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study
por: Moes, Harmen R., et al.
Publicado: (2020)

Combined multidisciplinary in/outpatient rehabilitation delays definite nursing home admission in advanced Parkinson’s disease patients
por: Steendam-Oldekamp, Elien, et al.
Publicado: (2023)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
por: Pedersen, Stephen W, et al.
Publicado: (2017)

Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries
por: Antonini, Angelo, et al.
Publicado: (2022)

Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology
por: Boertien, Jeffrey M., et al.
Publicado: (2020)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
por: Antonini, Angelo, et al.
Publicado: (2022)

Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease
por: Buhidma, Yazead, et al.
Publicado: (2020)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
por: Todorova, Antoniya, et al.
Publicado: (2014)

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
por: van Wamelen, Daniel J., et al.
Publicado: (2018)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
por: Titova, Nataliya, et al.
Publicado: (2017)

Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review
por: Smilowska, Katarzyna, et al.
Publicado: (2021)

Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far
por: Boura, Iro, et al.
Publicado: (2022)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson’s disease: Results from a data-driven approach
por: van der Zee, Sygrid, et al.
Publicado: (2022)

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
por: Sulzer, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1q6boj16o6t26gi1psam4lg8vu